SanBio Co Ltd
SanBio Co Ltd is a biotechnology company focused on developing regenerative medicine and cell therapy products, primarily targeting neurological and cardiovascular diseases.
Business. SanBio Co Ltd (4592.T) is a biotechnology and medical research company headquartered in Japan. The firm operates within the pharmaceuticals and medical research industry, focusing on product sales. It is primarily listed on the Tokyo Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
5 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
SanBio Co Ltd (4592.T) is a biotechnology and medical research company headquartered in Japan. The firm operates within the pharmaceuticals and medical research industry, focusing on product sales. It is primarily listed on the Tokyo Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.
SanBio maintains a strong liquidity position, with cash and equivalents amounting to ¥15,083.23 million, significantly exceeding its total liabilities of ¥2,016.87 million. The company's liquidity FPT (free cash flow to total liabilities) is robust, and its current ratio of 28.99 indicates a high ability to meet short-term obligations.
The company's profitability is currently negative, with a return on equity (ROE) of -28.24% and a return on assets (ROA) of -24.6%. These figures are below the typical thresholds for industry leaders in biotechnology, which often aim for ROE above 10% and ROA above 5%. The negative returns reflect ongoing R&D investments and the absence of commercialized products generating revenue.
SanBio's revenue is not disclosed by segment or geography in the available data, but the company is primarily focused on the Japanese market. Given the nature of its operations, it is likely that a significant portion of its R&D and clinical trials are conducted in Japan, with potential future expansion into other markets. However, the lack of geographic diversification could pose a concentration risk.
The company's growth trajectory is currently constrained by its negative operating and net income. Analysts have assigned a mean price target of ¥2,100.00, with a median of ¥2,000.00, but no strong buy or buy recommendations have been issued. The absence of positive analyst sentiment suggests uncertainty about the company's ability to achieve profitability in the near term.
Risk factors include the high costs and long timelines associated with biotechnology R&D, regulatory hurdles, and the competitive landscape in regenerative medicine. The company has not issued any recent equity, and dilution risk is currently low. However, the need for continued capital to fund operations could increase dilution pressure in the future.
Recent filings and transcripts do not indicate any major corporate events or strategic shifts. The company remains focused on its pipeline of cell therapy products, with no significant changes in its capital structure or business strategy reported in the latest available data.
- SanBio has a strong liquidity position with ¥15,083.23 million in cash and equivalents.
- The company is currently unprofitable, with ROE and ROA of -28.24% and -24.6%, respectively.
- Analysts have not issued any strong buy or buy recommendations, reflecting uncertainty about near-term profitability.
- The company's operations are concentrated in Japan, with no disclosed geographic diversification.
- No immediate dilution or liquidity risks are present, but continued R&D funding may increase future dilution pressure.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -40,69 |
| Revenue | —no estimate | —no estimate | 3,5B JPY |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- SanBio Co Ltd Market data — financials · 2026-05-26
- SanBio Co Ltd Market data — analyst estimates · 2026-05-26